ANIXA BIOSCIENCES, INC. (ANIX) EBITDA
- 2026-07-31: Basis Reported; EBITDA (m); Operating income -$2.74M; Depreciation and amortization (m).
- 2026-04-30: Basis Reported; EBITDA (m); Operating income -$2.65M; Depreciation and amortization (m).
- 2026-01-31: Basis Reported; EBITDA (m); Operating income -$2.72M; Depreciation and amortization (m).
- 2025-07-31: Basis Reported; EBITDA (m); Operating income -$2.44M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | Reported | (m) | -$2.74M | (m) | (m) | (m) | (m) | -$1.77M* | (m) | $1.33M | (m) | (m) |
| 2026-04-30 | Reported | (m) | -$2.65M | (m) | (m) | (m) | (m) | -$1.74M* | (m) | $1.26M | (m) | (m) |
| 2026-01-31 | Reported | (m) | -$2.72M | (m) | (m) | (m) | (m) | -$2.61M | (m) | $1.10M | (m) | (m) |
| 2025-07-31 | Reported | (m) | -$2.44M | (m) | (m) | (m) | (m) | -$1.51M* | (m) | $1.05M | (m) | (m) |
| 2025-04-30 | Reported | (m) | -$3.00M | (m) | (m) | (m) | (m) | -$1.50M* | (m) | $1.32M | (m) | (m) |
| 2025-01-31 | Reported | (m) | -$3.39M | (m) | (m) | (m) | (m) | -$2.90M | (m) | $1.55M | (m) | (m) |
| 2024-07-31 | Reported | (m) | -$3.59M | (m) | (m) | (m) | (m) | -$2.64M* | (m) | $1.93M | (m) | (m) |
| 2024-04-30 | Reported | (m) | -$3.47M | (m) | (m) | (m) | (m) | -$1.46M* | (m) | $1.65M | (m) | (m) |
| 2024-01-31 | Reported | (m) | -$3.61M | (m) | (m) | (m) | (m) | -$2.31M | (m) | $1.35M | (m) | (m) |
| 2023-07-31 | Reported | (m) | -$2.84M | (m) | $0.00* | (m) | (m) | -$1.45M* | (m) | $1.09M | (m) | (m) |
| 2023-04-30 | Reported | (m) | -$2.56M | (m) | $210.00K | (m) | (m) | -$807.00K* | (m) | $998.00K | (m) | (m) |
| 2023-01-31 | Reported | (m) | -$2.56M | (m) | (m) | (m) | (m) | -$1.99M | (m) | $1.07M | (m) | (m) |
| 2022-07-31 | Reported | (m) | -$2.80M | (m) | (m) | (m) | (m) | -$1.40M* | (m) | $1.45M | (m) | (m) |
| 2022-04-30 | Reported | (m) | -$3.59M | (m) | (m) | (m) | (m) | -$2.31M* | (m) | $1.74M | (m) | (m) |
| 2022-01-31 | Reported | (m) | -$3.88M | (m) | (m) | (m) | (m) | -$1.20M | (m) | $1.84M | (m) | (m) |
| 2021-07-31 | Reported | (m) | -$4.39M | (m) | $0.00* | (m) | (m) | -$1.48M* | (m) | $2.17M | (m) | (m) |
| 2021-04-30 | Reported | (m) | -$2.44M | (m) | $0.00* | (m) | (m) | -$1.24M* | (m) | $1.02M | (m) | (m) |
| 2021-01-31 | Reported | (m) | -$2.23M | (m) | $513.00K | (m) | (m) | -$1.17M | (m) | $828.00K | (m) | (m) |
| 2020-07-31 | Reported | (m) | -$2.44M | (m) | (m) | (m) | $0.00* | -$1.29M* | (m) | $1.25M | (m) | (m) |
| 2020-04-30 | Reported | (m) | -$2.67M | (m) | (m) | (m) | $1.00* | -$1.56M* | (m) | $1.23M | $1.44M | (m) |
| 2020-01-31 | Reported | (m) | -$2.63M | (m) | (m) | (m) | $15.79K | -$1.91M | (m) | $1.49M | $1.14M | (m) |
| 2019-07-31 | Reported | (m) | -$2.18M | (m) | (m) | (m) | $0.00* | -$640.10K* | (m) | $1.09M | $1.06M | (m) |
| 2019-04-30 | Reported | (m) | -$2.59M | (m) | (m) | (m) | (m) | -$1.43M* | (m) | $1.27M | $1.28M | (m) |
| 2019-01-31 | Reported | (m) | -$4.98M | (m) | (m) | (m) | (m) | -$1.33M | (m) | $2.25M | $2.07M | (m) |
| 2018-07-31 | Reported | (m) | -$5.61M | (m) | (m) | (m) | $20.04K* | -$1.17M* | (m) | $2.94M | $2.70M | (m) |
| 2018-04-30 | Reported | (m) | -$1.40M | (m) | (m) | (m) | $9.29K* | -$742.49K* | (m) | $660.19K | $908.77K | (m) |
| 2018-01-31 | Reported | (m) | -$1.87M | (m) | (m) | (m) | $2.52K | -$1.34M | (m) | $777.87K | $990.04K | (m) |
| 2017-07-31 | Reported | (m) | -$1.73M | (m) | (m) | (m) | $2.76K* | -$1.25M* | (m) | $362.97K | $1.51M | (m) |
| 2017-04-30 | Reported | (m) | -$1.21M | (m) | (m) | (m) | $0.00* | -$1.08M* | (m) | $431.12K | $699.35K | (m) |
| 2017-01-31 | Reported | (m) | -$1.39M | (m) | (m) | (m) | $14.12K | -$729.91K | (m) | $451.63K | $859.88K | (m) |
| 2016-07-31 | Reported | (m) | -$974.88K | (m) | (m) | (m) | $3.54K* | -$814.69K* | (m) | $292.06K | $631.23K | (m) |
| 2016-04-30 | Reported | (m) | -$1.15M | (m) | (m) | (m) | $35.10K* | -$1.35M* | (m) | $392.59K | $658.95K | (m) |
| 2016-01-31 | Reported | (m) | -$1.47M | (m) | (m) | (m) | $106.01K | -$532.38K | (m) | $458.05K | $873.42K | (m) |
| 2015-07-31 | Reported | (m) | -$1.49M | (m) | (m) | (m) | $0.00* | -$708.55K* | (m) | (m) | $1.42M | (m) |
| 2015-04-30 | Reported | (m) | -$2.13M | (m) | (m) | (m) | $0.00* | -$1.78M* | (m) | (m) | $1.96M | (m) |
| 2015-01-31 | Reported | (m) | $3.86M | (m) | (m) | (m) | $54.78K | $4.65M | (m) | (m) | $1.77M | (m) |
| 2014-07-31 | Reported | (m) | -$159.58K | (m) | (m) | (m) | (m) | -$337.35K* | (m) | (m) | $1.10M | (m) |
| 2014-04-30 | Reported | (m) | -$1.36M | (m) | (m) | (m) | (m) | -$507.80K* | (m) | (m) | $1.84M | (m) |
| 2014-01-31 | Reported | (m) | -$1.96M | (m) | (m) | (m) | (m) | -$1.17M | (m) | (m) | $1.86M | (m) |
| 2013-07-31 | Reported | (m) | -$2.22M | (m) | (m) | (m) | $1.10K* | -$839.66K* | (m) | (m) | $2.20M | (m) |
| 2013-04-30 | Reported | (m) | -$1.85M | (m) | (m) | (m) | -$1.75K* | -$912.73K* | (m) | (m) | $1.84M | (m) |
| 2013-01-31 | Reported | (m) | -$2.07M | (m) | (m) | (m) | $2.46K | -$890.01K | (m) | (m) | $2.07M | (m) |
| 2012-07-31 | Reported | (m) | -$643.34K | (m) | (m) | (m) | $0.00* | -$628.44K* | (m) | $458.41K | $433.68K | (m) |
| 2012-04-30 | Reported | (m) | -$878.20K | (m) | (m) | (m) | $750.00* | -$892.61K* | (m) | $604.21K | $521.56K | (m) |
| 2012-01-31 | Reported | (m) | -$887.26K | (m) | (m) | (m) | $850.00 | -$657.26K | (m) | $649.68K | $686.03K | (m) |
| 2011-07-31 | Reported | (m) | -$1.21M | (m) | (m) | (m) | $575.00* | $1.33M* | (m) | $879.64K | $774.75K | $600.00K |
| 2011-04-30 | Reported | (m) | -$1.29M | (m) | (m) | (m) | $2.21K* | -$726.07K* | (m) | $731.81K | $618.01K | (m) |
| 2011-01-31 | Reported | (m) | -$1.53M | (m) | (m) | (m) | $6.25K | -$609.65K | (m) | $776.91K | $760.98K | (m) |
| 2010-07-31 | Reported | (m) | -$1.27M | (m) | (m) | (m) | (m) | (m) | (m) | $673.32K | $620.97K | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-31 | Reported | (m) | -$11.70M | (m) | (m) | (m) | (m) | -$7.17M | (m) | $5.07M | (m) | (m) |
| 2024-10-31 | Reported | (m) | -$13.83M | (m) | (m) | (m) | (m) | -$7.33M | (m) | $6.40M | (m) | (m) |
| 2023-10-31 | Reported | (m) | -$11.01M | (m) | $210.00K | (m) | (m) | -$6.21M | (m) | $4.77M | (m) | (m) |
| 2022-10-31 | Reported | (m) | -$13.88M | (m) | (m) | (m) | (m) | -$6.49M | (m) | $6.70M | (m) | (m) |
| 2021-10-31 | Reported | (m) | -$13.14M | (m) | $512.00K | (m) | (m) | -$4.94M | (m) | $6.19M | (m) | (m) |
| 2020-10-31 | Reported | (m) | -$9.98M | (m) | (m) | (m) | $15.79K | -$6.18M | (m) | $4.38M | (m) | (m) |
| 2019-10-31 | Reported | (m) | -$11.89M | (m) | $250.00K | (m) | $175.46K | -$4.74M | (m) | $5.47M | $5.66M | (m) |
| 2018-10-31 | Reported | (m) | -$14.29M | (m) | (m) | (m) | $38.40K | -$4.27M | (m) | $6.81M | $6.91M | (m) |
| 2017-10-31 | Reported | (m) | -$6.08M | (m) | (m) | (m) | $30.19K | -$3.80M | (m) | $1.60M | $4.41M | (m) |
| 2016-10-31 | Reported | (m) | -$4.51M | (m) | (m) | (m) | $146.52K | -$3.38M | (m) | $1.56M | $2.71M | (m) |
| 2015-10-31 | Reported | (m) | -$944.76K | (m) | (m) | (m) | $54.78K | $1.36M | (m) | $711.39K | $5.51M | (m) |
| 2014-10-31 | Reported | (m) | -$5.04M | (m) | (m) | (m) | $6.68K | -$2.38M | (m) | (m) | $6.41M | (m) |
| 2013-10-31 | Reported | (m) | -$7.92M | (m) | (m) | (m) | (m) | -$3.19M | (m) | (m) | $7.99M | (m) |
| 2012-10-31 | Reported | (m) | -$4.13M | (m) | (m) | (m) | $1.60K | -$3.14M | (m) | $2.21M | $2.86M | (m) |
| 2011-10-31 | Reported | (m) | -$5.03M | (m) | (m) | (m) | $9.03K | -$716.00K | (m) | $3.12M | $2.87M | $600.00K |
| 2010-10-31 | Reported | (m) | -$5.25M | (m) | (m) | (m) | $2.07K | -$2.41M | (m) | $3.01M | $2.89M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |